Citi Group Entities Exit Substantial Holder Status in Telix Pharmaceuticals

Telix Pharmaceuticals ( (AU:TLX) ) has shared an announcement.

Citigroup Global Markets Australia and related Citi group entities have notified Telix Pharmaceuticals that they have ceased to be a substantial holder in the company as of 31 March 2026. The change reflects a series of adjustments in relevant interests tied to securities lending arrangements and ordinary-course stock market transactions involving Telix’s ordinary fully paid shares.

The notice details decreased holdings by Citibank N.A. Sydney Branch, Citigroup Global Markets Australia Pty Limited and Citigroup Global Markets Limited, partly offset by an increased interest held by Citigroup Global Markets Inc. The reshuffling of positions alters Citi’s aggregate exposure to Telix but appears driven by routine securities lending and trading activity rather than a disclosed shift in strategic stance toward the biotech group.

The most recent analyst rating on (AU:TLX) stock is a Buy with a A$14.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.

More about Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a listed biopharmaceutical company focused on developing and commercialising radiopharmaceutical products. Its ordinary fully paid shares trade under the ticker TLX, attracting interest from major global financial institutions and securities lenders active in Australian equity markets.

Average Trading Volume: 3,078,644

Technical Sentiment Signal: Hold

Current Market Cap: A$4.63B

See more data about TLX stock on TipRanks’ Stock Analysis page.